With regard to trial design, our population of baseline ESA nonusers—particularly the subset of with baseline Hb 8–10 g/dL— should be a good benchmark of expected event rates in the control group for placebo controlled randomized trials of anemia therapies in pre-dialysis CKD. Here, GSTM1 is linked to anemia.